Risk Evaluation for SARS-CoV-2 Variant Under Monitoring: PJ.2.1

Overview

PJ.2.1, a JN.1-descendant SARS-CoV-2 lineage, has been designated a variant under monitoring (VUM)
with increasing proportions globally, driven largely by detections in the region of the Americas (AMR),
particularly in Canada and the United States of America. Considering the available evidence, the additional
public health risk posed by PJ.2.1 is evaluated as low at the global level, with low confidence. The lineage
emerged through a saltation event and shows high human ACE2-binding capability. Available phenotypic
evidence indicates limited additional antibody escape relative to the contemporary variants tested, and
sera from recipients of LP.8.1- and XFG-adapted vaccines neutralized PJ.2.1 in laboratory assays.
Comparative clinical data are insufficient to determine whether PJ.2.1 is associated with increased disease
severity.

 

 

WHO Team
Epidemic and Pandemic Management (EPM)
Editors
World Health Organization
Number of pages
7